Bio tech company updates — 4/28/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korean biotech is riding a significant growth wave, with listed bio-healthcare firms posting 36.2 trillion won in revenue and Novo Holdings committing 100 billion won to the sector. Meanwhile, the BIOSECURE Act continues to redirect global CDMO investment toward Songdo, and German-Korean startup Koralo has announced a clinical research update and expansion strategy.
Key Findings
-
Korean listed bio-healthcare firms posted 36.2 trillion won in total revenue in 2025, up 11% year-on-year, with exports surging 15.9% to 14.74 trillion won.
-
Novo Holdings, the parent of Novo Nordisk and largest shareholder of Wegovy maker, announced it will invest 100 billion won in Korea's biohealth sector via Premier Partners' blind fund.
-
BIOSECURE Act fallout continues to reshape Korea's CDMO landscape, with an estimated $30 billion redirected toward Songdo, benefiting Samsung Biologics, Lotte, and Celltrion.
-
German-Korean biotech startup Koralo announced a clinical research update and outlined an expansion strategy, signaling growing cross-border collaboration in the Korean biotech space.
Details
Record Revenue for Korean Bio-Healthcare Listed Firms
Korea's listed bio-healthcare companies delivered a landmark performance in 2025, with combined revenues reaching 36.2 trillion won — an 11% increase over the prior year. Export growth was even more striking, climbing 15.9% to 14.74 trillion won, underscoring the sector's deepening global footprint.
Novo Holdings Makes Major Korea Biohealth Bet
In a signal of strong international confidence in Korea's life sciences ecosystem, Novo Holdings — the parent company of Novo Nordisk and largest shareholder of Wegovy's manufacturer — announced it will commit 100 billion won to Korea's biohealth sector. The investment will flow through Premier Partners' blind fund, making it one of the most notable foreign institutional investments in Korean biohealth this year.
BIOSECURE Act Drives $30B CDMO Windfall to Songdo
The geopolitical reverberations of the BIOSECURE Act continue to benefit Korea's contract development and manufacturing organizations (CDMOs). According to a new analysis, approximately $30 billion in pharmaceutical manufacturing investment has been redirected toward Songdo, Korea's purpose-built bio cluster. Samsung Biologics, Lotte Biologics, and Celltrion are among the primary beneficiaries as global pharma companies accelerate their pivot away from Chinese CDMOs.
Koralo: German-Korean Cross-Border Biotech Advances Clinically
German-Korean biotech startup Koralo announced an update on its ongoing clinical research and development activities, alongside a new expansion strategy. The announcement highlights the growing trend of transatlantic and cross-border biotech collaboration centered on Korea. No specific trial phase or indication details were disclosed in the available report.
Sources
- Seoul Economic Daily — Korean Biotech Listed Firms' Revenue Tops 36 Trillion Won:
- Seoul Economic Daily — Novo Holdings to Invest 100 Billion Won in Korean Biohealth Sector:
- Seoulz — Korea K-Bio CDMO 2026: How BIOSECURE Reshaped Songdo:
- Norfolk Daily News — German-Korean Biotech Startup Koralo Announces Clinical Research Update and Expansion Strategy:
Korea K-Bio CDMO 2026: How BIOSECURE Reshaped Songdo - Seoulz Korea K-Bio CDMO 2026: How BIOSECURE R
K-Biotech 2026: The 3 Korean Startups Big Pharma Can
Eli Lilly Visits Korea to Unveil Biotech Incubation Strategy With Samsung Biologics - Seoul Economic
en.sedaily.com
en.sedaily.com
norfolkdailynews.com
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
